BioSpace News Archive

Deals

Gilead to Acquire Immuno-Oncology Company Forty Seven for $4.9 Billion

“This agreement builds on Gilead’s presence in immuno-oncology and adds significant potential to our clinical pipeline,” said Daniel O’Day, Gilead’s chairman and chief executive officer.

March 2, 2020
·
3 min read
·
Mark Terry
Biotech Bay

Musculoskeletal Pains Market Growth Drive by the Rising Sporting Activities

Musculoskeletal pain is pain that affects bones, muscles, or the various types of connective tissues that hold the two together, such as tendons and ligaments.

March 2, 2020
·
4 min read
Biotech Bay

Outpatient Clinics Market Detailed Analysis and Forecast by 2025

According to a new research study by TMR research, the global outpatient clinics market is experiencing a high growth rate.

March 2, 2020
·
3 min read
Biotech Bay

Structural Heart Devices Market Growth Drive by the Research Activities

The structural heart devices market has gained weightage in the recent years due to the uncompromising rise in mitral regurgitation, aortic stenosis, and other related heart diseases.

March 2, 2020
·
4 min read
Business

BIO Taps George Scangos to Helm Response to Coronavirus Outbreak

Scangos, who currently helms Vir Biotechnology, is expected to coordinate the industry’s response to the increasing coronavirus threat.

March 2, 2020
·
2 min read
·
Alex Keown
Pharm Country

Depression Drugs Market: Middle East & Africa to Offer Significant Incremental Opportunity, TMR

The demand within the global market for depression drugs has been rising alongside growing incidence of mental disorders.

March 2, 2020
·
4 min read
Pharm Country

Advanced Wound Care Management Raises Strong Demand with Rising Incidence of Diabetes and Other Chronic Diseases, TMR

The global advanced wound care management market is prognosticated to push its growth as chronic diseases show high prevalence in different parts of the world.

March 2, 2020
·
4 min read
Drug Development

EyePoint Reports Long-Term Positive Results from Phase III Yutiq Trial

EyePoint Pharmaceuticals announced positive topline 36-month follow-up data from the second Phase III trial of Yutiq (fluocinolone acetonide intravitreal implant) for treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.

March 2, 2020
·
2 min read
·
Mark Terry
GlaxoSmithKline Reportedly Trying to Sell Some of its Antibiotics Portfolio

The drugs in question bring in about $200 million annually.

March 2, 2020
·
3 min read
·
Mark Terry
Career Advice

This Method Will Make Your Job Search More Productive

Once you have your job search spreadsheet organized and the hunt is officially underway, complete the tasks that come up with this method in mind.

March 2, 2020
·
2 min read
·
Laura Brothers